NCT05787028View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Alzheimer's Disease
Interventions
DRUG

AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg

Take one AD16 tablet in the morning

DRUG

AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg

Participants will take a placebo pill matching AD16 once in the morning

Trial Locations (1)

Unknown

The Central South University Xiang Ya Hospital, Changsha

All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

lead

South China Center For Innovative Pharmaceuticals

OTHER

NCT05787028 - Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration | Biotech Hunter | Biotech Hunter